Bumrungrad International Hospital
| Thailand | Turkey | South Korea | |
| Target therapy for lung cancer | - | from AUD $7,209 / ฿A245,115 | from AUD $4,470 / ฿A151,971 |
No hidden fees – just official clinic prices. Pay at the clinic for Target therapy for lung cancer upon arrival and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Target therapy for lung cancer and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Target therapy for lung cancer journey.
Oncologists in Thailand determine eligibility for targeted lung cancer therapy through molecular biomarker testing and genetic tumour analysis. Specialists at JCI-accredited centres like Bumrungrad International Hospital identify specific mutations, such as EGFR or ALK. This confirms the cancer responds to precision drugs.
Bookimed Expert Insight: Thai oncology centres specialise in EGFR mutations, which appear in 50% of Asian non-smokers with lung cancer. Leading facilities like Bumrungrad International Hospital use telemedicine to review pathology reports before patients fly. This can save weeks of waiting for diagnostic results in Bangkok.
Patient Consensus: Tests in Thailand are thorough. Doctors identify the specific mutations that drive the cancer. Bringing previous pathology results speeds up the process. The staff focus on finding the most precise treatment plan for each case.
When lung cancer resists targeted therapy in Thailand, specialists pivot to next-line protocols. These follow Pan-Asian ESMO guidelines. This process involves repeat biomarker testing to identify new mutations. Doctors then switch to drugs like third-generation TKIs, platinum-doublet chemotherapy, or stereotactic radiation.
Bookimed Expert Insight: Thailand is a regional leader with 150+ clinics specialising in targeted therapy. Leading facilities like Bumrungrad International Hospital serve over 500,000 international patients annually. This volume means oncologists have seen virtually every resistance pattern. This includes secondary T790M mutations and small cell transformations.
Patient Consensus: Patients find that resistance is often detected on routine scans before symptoms appear. Keeping digital records of pathology helps Thai teams act quickly if drugs change. Continuity of care is essential. Confirm that second-line drugs are available before travelling.
Targeted therapy for lung cancer is a precision medicine. It blocks specific genetic mutations, such as EGFR or ALK, that drive tumour growth. Unlike chemotherapy, which kills all rapidly dividing cells, targeted drugs spare healthy tissue to minimise side effects.
Bookimed Expert Insight: While chemotherapy is standard, high-volume centres in Bangkok perform molecular testing for EGFR, ALK, and ROS1 mutations. Bumrungrad International Hospital serves over 500,000 international patients annually. This scale means their labs have the experience needed to identify rare biomarkers.
Patient Consensus: Patients in Thailand found that targeted therapy felt less aggressive than traditional chemo. They suggest requesting all molecular pathology reports in English to help with future care.
Targeted therapy in Thailand is only suitable for non-small cell lung cancer (NSCLC) with specific genetic mutations. It is not an option for small cell lung cancer (SCLC). Suitability requires biomarker testing to identify drivers like EGFR, ALK, or ROS1 before starting treatment.
Bookimed Expert Insight: Targeted drugs are available at 150+ Thai clinics. High-volume centres like Bumrungrad handle 500,000+ international patients yearly. Their scale provides immediate access to molecular testing and drug varieties that smaller clinics often lack.
Patient Consensus: Patients find that full molecular profiling in Thailand is essential for a clear plan. They value the kind, helpful staff and the ability to continue monitoring through telemedicine once they return home.
Thailand's leading oncology centres for targeted therapy include Bumrungrad International Hospital, Wattanosoth Cancer Hospital, and MedPark Hospital. These Bangkok-based facilities specialise in molecular diagnostics for EGFR and ALK mutations. They hold JCI accreditation and provide high-quality care for patients with lung cancer.
Bookimed Expert Insight: Bumrungrad International Hospital serves over 500,000 international patients annually. It holds Global Healthcare Accreditation (GHA). This certification ensures their processes are purpose-built for foreign patients. This makes logistics and medical record transfers much smoother for those travelling from Australia.
Patient Consensus: Fast molecular testing and accessing the right oncologist are more important than hospital amenities. Patients in Thailand suggest bringing all existing pathology and imaging reports to avoid treatment delays.
Targeted therapy in Thailand is given as daily oral tablets or via intravenous infusions at a specialist oncology centre. Delivery depends on genetic mutations found through molecular profiling. Most patients attend outpatient clinics for monitoring while staying in nearby serviced apartments.
Bookimed Expert Insight: Bumrungrad International Hospital serves over 1,000,000 patients annually with half coming from overseas. This massive international volume means their oncology teams are highly efficient. They coordinate with Australian GPs to keep long-term treatment plans consistent once the patient returns home.
Patient Consensus: Patients find the coordination teams very helpful and punctual during their stay in Thailand. Most recommend confirming whether therapy is oral or intravenous before travel to plan accommodation properly.